| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original Articles |
From the Medical Care Center Prof Mathey, Prof Schofer and Hamburg University Cardiovascular Center (J.S., M.S., T.T., A.P.), and Departments of Cardiovascular Surgery (H.T., H.R.) and Cardiology/Angiology (O.W.F., T.M.), University Heart Center Hamburg, Hamburg, Germany; Division of Cardiovascular Medicine, University of California, Davis Medical Center, Sacramento, Calif (R.I.L.); and University of Michigan Cardiovascular Center, Ann Arbor, Mich (S.F.B.).
Correspondence to Michael Schlüter, PhD, Medical Care Center Prof Mathey, Prof Schofer, Wördemanns Weg 25-27, 22527 Hamburg, Germany. E-mail schlueter{at}herz-hh.de
Received June 19, 2008; accepted August 20, 2008.
Background— To assess the feasibility and safety of retrograde transarterial implantation of a novel nonmetallic aortic valve prosthesis (Direct Flow Medical Inc, Santa Rosa, Calif), a prospective single-center study was performed in patients with severe aortic stenosis at high risk for open-heart surgery.
Methods and Results— Fifteen patients (intention-to-treat cohort) with an aortic valve area
0.8 cm2, a
35-mm Hg mean transvalvular pressure gradient, and a logistic EuroSCORE
20% were enrolled. Percutaneous aortic valve replacement was performed with the patient under general anesthesia. Hemodynamic parameters were assessed before and after implantation by transesophageal echocardiography. Clinical follow-up and transthoracic echocardiographic assessment were obtained at 30 days. Procedural success was achieved in 12 patients (80%). Surgical conversion became necessary at day 2 in 1 patient; 11 patients (73%) were discharged with a permanent implant. In these patients, implantation resulted acutely in a significant increase in aortic valve area (median, 1.64 [interquartile range, 1.27 to 1.74] versus 0.60 [0.46 to 0.69] cm2; P=0.0033) and a concomitant reduction in the mean pressure gradient (14.0 [13.2 to 16.5] versus 54.0 [43.2 to 59.8] mm Hg; P=0.0033). At 30 days, 1 cardiac death (6.7%; 95% CI, 0.2% to 32.0%) and 1 major stroke were observed. The 10 surviving patients with a permanent implant showed marked hemodynamic and clinical improvement at this time point.
Conclusions— In this small series of patients, percutaneous implantation of the Direct Flow Medical aortic valve prosthesis in high–surgical-risk patients was feasible and associated with a reasonably low safety profile.
Key Words: aorta catheterization prosthesis stenosis valves
Related Article
This article has been cited by other articles:
![]() |
S. R. Dixon, C. L. Grines, and W. W. O'Neill The year in interventional cardiology. J. Am. Coll. Cardiol., June 2, 2009; 53(22): 2080 - 2097. [Full Text] [PDF] |
||||
|
Home | Subscriptions | Archives | Feedback | Authors | Help | Circulation Journals Home | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |